481 related articles for article (PubMed ID: 35999218)
1. Classical epithelial-mesenchymal transition (EMT) and alternative cell death process-driven blebbishield metastatic-witch (BMW) pathways to cancer metastasis.
Jinesh GG; Brohl AS
Signal Transduct Target Ther; 2022 Aug; 7(1):296. PubMed ID: 35999218
[TBL] [Abstract][Full Text] [Related]
2. Ferroptosis and EMT: key targets for combating cancer progression and therapy resistance.
Ren Y; Mao X; Xu H; Dang Q; Weng S; Zhang Y; Chen S; Liu S; Ba Y; Zhou Z; Han X; Liu Z; Zhang G
Cell Mol Life Sci; 2023 Aug; 80(9):263. PubMed ID: 37598126
[TBL] [Abstract][Full Text] [Related]
3. The novel role of Yin Yang 1 in the regulation of epithelial to mesenchymal transition in cancer via the dysregulated NF-κB/Snail/YY1/RKIP/PTEN Circuitry.
Bonavida B; Baritaki S
Crit Rev Oncog; 2011; 16(3-4):211-26. PubMed ID: 22248055
[TBL] [Abstract][Full Text] [Related]
4. Hybrid epithelial/mesenchymal phenotypes promote metastasis and therapy resistance across carcinomas.
Jolly MK; Somarelli JA; Sheth M; Biddle A; Tripathi SC; Armstrong AJ; Hanash SM; Bapat SA; Rangarajan A; Levine H
Pharmacol Ther; 2019 Feb; 194():161-184. PubMed ID: 30268772
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic implications of cancer epithelial-mesenchymal transition (EMT).
Cho ES; Kang HE; Kim NH; Yook JI
Arch Pharm Res; 2019 Jan; 42(1):14-24. PubMed ID: 30649699
[TBL] [Abstract][Full Text] [Related]
6. OVOL2 links stemness and metastasis via fine-tuning epithelial-mesenchymal transition in nasopharyngeal carcinoma.
Qi XK; Han HQ; Zhang HJ; Xu M; Li L; Chen L; Xiang T; Feng QS; Kang T; Qian CN; Cai MY; Tao Q; Zeng YX; Feng L
Theranostics; 2018; 8(8):2202-2216. PubMed ID: 29721073
[No Abstract] [Full Text] [Related]
7. Crosstalk between ferroptosis and the epithelial-mesenchymal transition: Implications for inflammation and cancer therapy.
Ebrahimi N; Adelian S; Shakerian S; Afshinpour M; Chaleshtori SR; Rostami N; Rezaei-Tazangi F; Beiranvand S; Hamblin MR; Aref AR
Cytokine Growth Factor Rev; 2022 Apr; 64():33-45. PubMed ID: 35219587
[TBL] [Abstract][Full Text] [Related]
8. Ferroptosis and EMT resistance in cancer: a comprehensive review of the interplay.
Zhang H; Chen N; Ding C; Zhang H; Liu D; Liu S
Front Oncol; 2024; 14():1344290. PubMed ID: 38469234
[TBL] [Abstract][Full Text] [Related]
9. Epithelial, mesenchymal and hybrid epithelial/mesenchymal phenotypes and their clinical relevance in cancer metastasis.
Garg M
Expert Rev Mol Med; 2017 Mar; 19():e3. PubMed ID: 28322181
[TBL] [Abstract][Full Text] [Related]
10. EMT Transition States during Tumor Progression and Metastasis.
Pastushenko I; Blanpain C
Trends Cell Biol; 2019 Mar; 29(3):212-226. PubMed ID: 30594349
[TBL] [Abstract][Full Text] [Related]
11. Roles of Dietary Phytoestrogens on the Regulation of Epithelial-Mesenchymal Transition in Diverse Cancer Metastasis.
Lee GA; Hwang KA; Choi KC
Toxins (Basel); 2016 May; 8(6):. PubMed ID: 27231938
[TBL] [Abstract][Full Text] [Related]
12. Molecular Pathways Mediating Metastases to the Brain via Epithelial-to-Mesenchymal Transition: Genes, Proteins, and Functional Analysis.
Jeevan DS; Cooper JB; Braun A; Murali R; Jhanwar-Uniyal M
Anticancer Res; 2016 Feb; 36(2):523-32. PubMed ID: 26851006
[TBL] [Abstract][Full Text] [Related]
13. Targeting EMT in cancer: opportunities for pharmacological intervention.
Davis FM; Stewart TA; Thompson EW; Monteith GR
Trends Pharmacol Sci; 2014 Sep; 35(9):479-88. PubMed ID: 25042456
[TBL] [Abstract][Full Text] [Related]
14. The therapeutic potential of targeting the epithelial-mesenchymal transition in cancer.
Ginnebaugh KR; Ahmad A; Sarkar FH
Expert Opin Ther Targets; 2014 Jul; 18(7):731-45. PubMed ID: 24758643
[TBL] [Abstract][Full Text] [Related]
15. Epithelial-Mesenchymal Transition (EMT) as a Therapeutic Target.
Jonckheere S; Adams J; De Groote D; Campbell K; Berx G; Goossens S
Cells Tissues Organs; 2022; 211(2):157-182. PubMed ID: 33401271
[TBL] [Abstract][Full Text] [Related]
16. Epithelial Mesenchymal Transition in Aggressive Lung Cancers.
Mittal V
Adv Exp Med Biol; 2016; 890():37-56. PubMed ID: 26703798
[TBL] [Abstract][Full Text] [Related]
17. Epithelial-mesenchymal transition as a fundamental mechanism underlying the cancer phenotype.
Cervantes-Arias A; Pang LY; Argyle DJ
Vet Comp Oncol; 2013 Sep; 11(3):169-84. PubMed ID: 22404947
[TBL] [Abstract][Full Text] [Related]
18. MicroRNAs: critical regulators of epithelial to mesenchymal (EMT) and mesenchymal to epithelial transition (MET) in cancer progression.
Bullock MD; Sayan AE; Packham GK; Mirnezami AH
Biol Cell; 2012 Jan; 104(1):3-12. PubMed ID: 22188537
[TBL] [Abstract][Full Text] [Related]
19. Emerging Concepts of Hybrid Epithelial-to-Mesenchymal Transition in Cancer Progression.
Sinha D; Saha P; Samanta A; Bishayee A
Biomolecules; 2020 Nov; 10(11):. PubMed ID: 33207810
[TBL] [Abstract][Full Text] [Related]
20. MicroRNAs and epithelial-mesenchymal transition in prostate cancer.
Sekhon K; Bucay N; Majid S; Dahiya R; Saini S
Oncotarget; 2016 Oct; 7(41):67597-67611. PubMed ID: 27588490
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
